Clinical perspective
Targeted Therapies Are Reshaping the Future of CSU Management
Chronic spontaneous urticaria (CSU) is increasingly recognized as a complex inflammatory condition involving multiple immune pathways rather than a single disease mechanism. Although second-generation antihistamines remain an important component of treatment, many patients continue to experience recurring hives, itching, and angioedema. A 2026 review published in Pharmaceutics examines how advances in understanding CSU immunopathogenesis are supporting the development of targeted therapies and creating opportunities for more personalized approaches to disease management.
A central theme of the review is the growing recognition of distinct immunological endotypes within CSU. Researchers describe type I autoallergic and type IIb autoimmune mechanisms, both of which can contribute to mast cell activation and inflammatory symptoms. These differences may help explain why patients with similar clinical presentations experience varying levels of disease activity and respond differently to treatment. Understanding these underlying mechanisms is becoming increasingly important as therapeutic options expand.
The review explores several targeted treatment strategies that act on different components of the immune response. These include anti-IgE therapies, approaches targeting interleukin-4 and interleukin-13 signaling, Bruton's tyrosine kinase (BTK) inhibitors, and investigational therapies targeting the KIT receptor involved in mast cell biology. Clinical studies of these approaches have demonstrated encouraging results in selected CSU populations, although their mechanisms, evidence bases, safety considerations, and regulatory status differ. The expanding treatment landscape reflects growing interest in addressing the biological processes responsible for persistent disease activity.
Another area of investigation involves identifying biomarkers that could help predict treatment response. Researchers have examined total immunoglobulin E levels, anti-thyroid peroxidase antibodies, autologous serum skin testing, basophil activity, and changes in circulating inflammatory cells. Although these measures may provide insight into disease endotypes, their usefulness for selecting specific therapies remains insufficiently validated. Additional prospective studies are needed before biomarker-guided treatment selection can become a routine component of CSU management.
As targeted treatment options continue to evolve, the review highlights the potential for more individualized approaches to CSU care. Greater understanding of disease mechanisms may eventually help clinicians match therapeutic strategies to patient characteristics and underlying inflammatory pathways. However, further research is necessary to establish reliable predictors of response and determine how emerging treatments can be integrated into evidence-based clinical decision-making.
Original research: Andrzejczak K, et al. Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine. Pharmaceutics. 2026.